Knott David M Jr Increases Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Knott David M Jr grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 15.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 440,000 shares of the biotechnology company's stock after buying an additional 58,000 shares during the period. BioCryst Pharmaceuticals accounts for about 1.2% of Knott David M Jr's holdings, making the stock its 15th biggest holding. Knott David M Jr owned 0.21% of BioCryst Pharmaceuticals worth $3,309,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Xponance Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 9.1% in the 4th quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company's stock valued at $112,000 after purchasing an additional 1,242 shares during the period. Sei Investments Co. lifted its stake in BioCryst Pharmaceuticals by 2.8% in the fourth quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company's stock valued at $430,000 after buying an additional 1,537 shares during the period. Captrust Financial Advisors grew its position in shares of BioCryst Pharmaceuticals by 19.4% during the 3rd quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company's stock worth $124,000 after buying an additional 2,644 shares during the period. SkyView Investment Advisors LLC increased its stake in shares of BioCryst Pharmaceuticals by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company's stock valued at $99,000 after acquiring an additional 3,000 shares in the last quarter. Finally, Arizona State Retirement System lifted its position in shares of BioCryst Pharmaceuticals by 6.6% during the 4th quarter. Arizona State Retirement System now owns 57,001 shares of the biotechnology company's stock valued at $429,000 after acquiring an additional 3,518 shares during the period. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock traded down $0.50 during trading hours on Friday, reaching $6.83. The company had a trading volume of 3,506,819 shares, compared to its average volume of 2,774,572. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -11.20 and a beta of 1.84. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $9.50. The business has a fifty day simple moving average of $8.14 and a 200-day simple moving average of $7.80.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same quarter in the previous year, the business posted $0.28 EPS. The company's quarterly revenue was up 40.8% on a year-over-year basis. On average, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on BCRX shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $11.00 price target (up from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. JMP Securities reaffirmed a "market outperform" rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Needham & Company LLC increased their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Monday, January 13th. Wedbush started coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price objective for the company. Finally, Evercore ISI upped their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.57.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.